Corino Therapeutics, Inc. is a private, development-stage biopharmaceutical company focused on acquiring, developing, and commercializing innovative products for the treatment of a variety of human diseases, particularly orphan indications.  Corino develops technologies that address important unmet medical needs, and which offer improved, cost-effective alternatives to current methods of treatment.  Preclinical and early clinical data suggests that Corino's lead product candidate, CRX-1008, may provide a safe and effective treatment for all forms of Transthyretin Amyloidosis (ATTR).  Having been approved for nearly 20 years, the active compound in CRX-1008 has extensive safety and toxicity data.  Further, the compound's efficacy has been demonstrated in the new indication of ATTR.